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Inducedpluripotentstem(iPS)cellsaregeneratedbyreprogramminghumansomaticcellsthroughtheforcedexpressionofseveral
embryonic stem (ES) cell-speciﬁc transcription factors. The potential of iPS cells is having a signiﬁcant impact on regenerative
medicine, with the promise of inﬁnite self-renewal, diﬀerentiation into multiple cell types, and no problems concerning ethics
or immunological rejection. Human iPS cells are currently generated by transgene introduction principally through viral vectors,
which integrate into host genomes, although the associated risk of tumorigenesis is driving research into nonintegration methods.
Techniques for pluripotent stem cell diﬀerentiation and puriﬁcation to yield cardiomyocytes are also advancing constantly.
Although there remain some unsolved problems, cardiomyocyte transplantation may be a reality in the future. After those
problems will be solved, applications of human iPS cells in human cardiovascular regenerative medicine will be envisaged for
the future. Furthermore, iPS cell technology has generated new human disease models using disease-speciﬁc cells. This paper
summarizes the progress of iPS cell technology in cardiovascular research.
1.Introduction
Cardiovascular disease remains a major cause of mortality
in developed countries, with severe heart failure being the
leading cause of cardiac death [1]. There is no fundamen-
tal therapy for refractory heart failure other than heart
transplantation, which is not regarded as a robust option
because of the associated problems such as too few donors
and immunological rejection [2]. A clear need, therefore,
exists for novel therapies for severe cardiovascular disease,
and recent advances in stem cell biology have indicated that
regenerative medicine might meet that need in the future.
Stem cells are deﬁned by the characteristics of self-
renewal and diﬀerentiation capability to multiple tissues.
These cells thus hold great promise as a source for cell
transplantation therapy. Embryonic organs rapidly develop,
and embryonic cells have a strong proliferation potential.
In particular, embryonic stem (ES) cells that are established
from the inner cell mass of the morula stage of mammalian
embryos are regarded as a powerful cell source for clinical
application because of their promising growth potential and
pluripotency. However, there are major obstacles with the
use of human ES cells such as bioethical issues surrounding
the destruction of a fertilized egg and immune rejection due
to alloantigens following transplantation. Adult organs are
also seen as a potential source of somatic stem cells with the
ability to proliferate and diﬀerentiate into the speciﬁc cells
in each tissue and thus help to maintain tissue homeostasis
and organ healing after injury. Adult heart, for instance,
contains cardiac stem cells that can be diﬀerentiated into
mature cardiomyocytes and vascular cells, and is, therefore, a
candidate source for cardiac cell transplantation therapy [3,
4].However,therearenotsuﬃcientnumbersofsomaticstem
cells in adult organs and the proliferation and diﬀerentiation
ability of somatic stem cells is limiting compared to that of
ES cells.
The recent generation of induced pluripotent stem (iPS)
cells has created new hope in the ﬁeld of regenerative
medicine for overcoming the dilemma of ES cells. iPS cells
can be generated from somatic cells by introducing deﬁned
reprogramming factors (Oct3/4, Sox2, Klf4, c-Myc, Nanog,
and Lin28) in various mammals including mouse, rat, pig,
monkey, and human [5–10]. These cells have the two crucial
stem cell characteristics of self-renewal and pluripotency.
In addition, the ethical issues associated with generating
iPS cells are trivial compared to those for ES cells because2 Stem Cells International
the sacriﬁce of an embryo is dispensable, and the use of the
recipient’s own cells eliminates the risk of immune rejection
generally associated with transplantation. Because of these
tremendous beneﬁts, iPS cells hold great promise as a novel
cell source for regenerative medicine. Moreover, the unique
characteristics harbored in the genetic information of almost
every adult cell could allow the creation of patient-speciﬁc
pluripotent stem cells, which can be then dedicated to any
cell type in vitro. Consequently, iPS cell technology has
raised concerns in the ﬁelds of disease pathogenesis and drug
discovery [11–13].
2. iPS Induction Methods
ES cells have the ability to proliferate inﬁnitely and can
diﬀerentiate into the cell types of all three germ layers
with germ line transmission [14]. The ﬁrst human ES cells
were successfully generated in 1998 [15]. Human iPS cells
were established in 2007 by the transduction of various
gene cocktails [6, 7]. The characteristics of iPS cells are
quite similar to those of ES cells in terms of morphology,
proliferation ability, patterning of global gene expression,
and the epigenetic status of promoter regions for stem-cell-
speciﬁc transcription factors. As a matter of course, these iPS
cells also can diﬀerentiate into cells of the three germ layers
in vitro and in vivo.
For iPS cell technology to realize its signiﬁcant promise
for advanced regenerative medicine, several diﬃcult prob-
lems must be addressed. The original method of generating
iPS cells involves the transduction of core transcription
factors into somatic cells by retroviral vectors with the
accompanying insertion of transgenes into the host genome.
These transgenes could theoretically disrupt the native genes
and/or alter normal gene expression. Although the expres-
sion of such viral-mediated exogenous genes are virtually
silenced once the cells are fully reprogrammed into iPS cells,
small but sustained leakage of transgene expression or the
reactivation of those transgenes occasionally disturbs the
diﬀerentiation and maintenance of an undiﬀerentiated state
[16]. In particular, oncogenic transgene reactivation such as
thatofc-Myc couldincreasetheriskoftumorformationafter
transplantation of the iPS-derived cells [17]. In addition, the
detail mechanism of reprogramming is not yet elucidated
suﬃciently, and the reprogramming eﬃciency of somatic
cellsisstilllow.Theseproblemsneedtobeatleastminimized
beforetheapplicationofiPStechnologyintheclinicalsetting
can proceed.
To establish safer iPS cells, several novel methods are
being investigated that do not involve transgene insertions
into the host genome. Various gene-delivery systems have
been developed for the reprogramming of human somatic
cells into iPS cells [18–24]. In addition, some chemical
compounds can raise the reprogramming eﬃciency and
reduce the required number of the transducing factors to
generateiPScells[25–28]. There are many reports of somatic
cells being reprogrammed to iPS cells, although most cases
involve dermal ﬁbroblasts obtained from a dermal punch
biopsy, which leaves a small scar on the donor’s skin. Such
skin biopsies should be avoided to generate human iPS
cells. Recently, we and several other groups reported novel
methods for generating iPS cells less invasively from human
circulating peripheral blood cells [29–32]. Our method uses
Sendai viral systems to deliver the reprogramming factors
[33]. Sendai virus is categorized as a negative-strand RNA
virus that cannot integrate into the host genome, but can
highly infect activated T cells [34]. It is very important for
human clinical usage to obtain the nonintegration human
i P Sc e l le a s i l y ,s t a b l y ,a n de ﬃciently and attenuate the
physical invasion for donors to obtain somatic cells. These
improved methods can be helpful to extend the indication of
generating iPS cells and to be easily accessible to realize the
future clinical application of the iPS technology.
3. Differentiation into Cardiomyocytes from
PluripotentStemCells
ES cells and iPS cells can give rise to all cell types of all three
germ layers, using quite similar methodologies to control
the diﬀerentiation. In the conventional method, ES cell
diﬀerentiation is performed through embryoid bodies (EBs),
which are aggregates of ES cells maintained in suspension
cultures. In this section, we focus on the diﬀerentiation
systems for generating cardiomyocytes from ES cells and iPS
cells.
A recent report indicated no signiﬁcant diﬀerence in the
fundamental characteristics of cardiomyocytes diﬀerentiated
f r o me i t h e rE So ri P Sc e l l s[ 35–38]. However, the eﬃciency
of cardiogenesis from ES and iPS cells is still too low and not
suﬃciently stable to realize the goals of cardiac regenerative
medicine. Generally considered, the mechanisms of in vitro
diﬀerentiation from pluripotent stem cells are similar to
the regulatory mechanisms of normal early development.
To improve the eﬃciency of in vitro cardiogenesis, various
screens for essential signalling molecules in normal heart
development have been performed. Among several signal
proteins associated with cardiac development, canonical
Wnt/beta-catenin [39–42], activin/nodal [43, 44], and BMP
signaling [45–51] have the crucial roles in normal heart
development, and supplementation of those molecules into
ES/iPS cell diﬀerentiation systems could signiﬁcantly boost
the eﬃciency of cardiogenesis. Moreover, it also seems that
bidirectional stimulation in these pathways is necessary at
diﬀerent developmental stages [52, 53].
We previously reported that transit inhibition of BMP
signaling very early during diﬀerentiation is crucial for
cardiogenesis in murine ES cells [54]. Whole-mount in
situ hybridization for various BMP antagonists on mouse
embryos at diﬀerent developmental stages revealed that
noggin, a BMP antagonist, was expressed only brieﬂy in the
heart-forming area. This phenomenon was also observed in
early embryos of chick and Xenopus, suggesting a conserved
mechanism in heart development [55, 56]. We proposed
that administration of noggin before the EB formation stage
would mimic its transient and strong expression during
early gastrulation. Indeed, noggin administration around EB
formation day led to a marked increase in cardiogenesisStem Cells International 3
from murine ES cells. Other BMP antagonists also act to
increase cardiomyocyte diﬀerentiation eﬃciency, indicating
that transient relief from the intrinsic BMP signal is critical
for cardiomyocyte induction.
We also identiﬁed growth factors crucial for embry-
onic premature cardiomyocytes through the screening of
global gene expressions in noggin-treated mouse ES cell-
derived cardiomyocytes by microarray analysis [57]. We
found that the expression level of csf3r, which encodes the
granulocyte colony-stimulating factor receptor (G-CSFR),
was signiﬁcantly higher in cardiomyocyte-diﬀerentiating ES
cells [58], and conﬁrmed that both G-CSFR and G-CSF were
speciﬁcally but transiently expressed in embryonic mouse
heart at the midgestational stage. When extrinsic G-CSF
was administered to ES/iPS cell-derived cardiomyocytes, it
markedlyaugmentedtheirproliferation.Theseﬁndingsindi-
cated that G-CSF is critical for cardiomyocyte proliferation
and could be used to boost the yield of cardiomyocytes from
ES/iPS cells for their potential application in regenerative
medicine.
To some extent, we can manage to diﬀerentiate pluripo-
tentstemcellsintocardiomyocyteseﬀectivelyandcontrolthe
proliferationofprematurecardiomyocytes.However,human
heart is a large organ, and huge numbers of cardiomyocytes
would be needed for human cardiac regenerative therapy,
requiring even more sophisticated methods for cardiomy-
ocyte generation. To this end, prominent diﬀerences have
been demonstrated in the ability to diﬀerentiate into speciﬁc
lineage cells among iPS cell [59]. Moreover, their response to
various growth factor and cytokine stimulations also varied
markedly among cell lines. Recent studies have also demon-
strated that the characteristics of iPS cells are inﬂuenced
by the derived somatic cells according to their epigenetic
memory [60–62]. It would, therefore, be preferable to
ascertain which cell lines are the best sources of iPS cells for
e a c hl i n e a g ec e l ld i ﬀerentiation and what is the best way to
select such iPS cell lines before starting the diﬀerentiation.
4. Stem Cell-Based Cardiac Regeneration
ES and iPS cells both have the potential to be a deﬁnite cell
source for regenerative therapy because they can proliferate
inﬁnitely. In the cardiovascular ﬁeld, regenerative cell ther-
apy using pluripotent cells is expected to complement rather
than replace heart transplantation in the future [12, 63, 64].
Molecular biological and physiological studies have demon-
strated that ES and iPS cell-derived cardiomyocytes have
the required cardiovascular function [65–67]. iPS cells can
diﬀerentiate into several types of cardiomyocytes including
atrial, nodal, and ventricular cells, with similar properties
to native cardiomyocytes. Cardiomyocytes derived from iPS
cells properly express typical ion channels with the expected
functional responses to several ion channel blockers [68].
Therearealsomanyreportsthatthetransplantationofeither
cardiomyocytes or cardiac progenitor cells derived from
human ES cells into infarcted rodent heart could improve
cardiac function [50, 69, 70]. Transplanted ES/iPS cell-
derived cardiomyocytes were integrated into the infarcted
host heart and supplied working muscles functioning coop-
eratively, while the molecules secreted in a paracrine or
autocrine fashion from transplanted cells are also important.
It was also reported that the transplantation of iPS cells
into the postinfarcted heart of immunocompetent mouse
signiﬁcantly recovered the cardiac function of failing heart
and transplanted cells were successfully diﬀerentiated into
cardiomyocytes, smooth muscles, and endothelial cells in
the heart [71]. The precise mechanisms underpinning these
successful cell transplantations remain unclear. However,
accumulating evidence indicates that the transplantation
of iPS cell-derived cardiomyocytes will be a viable future
alternative for treating diseased heart.
One of the most critical issues in these eﬀorts is how to
eliminate undiﬀerentiated ES/iPS cells from the transplant-
ing cells. Undiﬀerentiated pluripotent stem cells implanted
into the recipient body increase concerns about tumors
like teratoma emerging from the transplanted cells [72].
Although it is not yet determined whether terminally diﬀer-
entiatedcellsorprogenitorcellsarebetterforcelltransplants,
undiﬀerentiated pluripotent stem cells need to be eliminated
from the equation before transplantation in any case to
relieve the risk of tumorigenesis. A variety of puriﬁcation
methodsforES/iPScell-deriveddiﬀerentiatedcellshavebeen
developed, with most involving gene manipulation to label
the selection marker such as GFP regulated under a speciﬁc
promoter[73,74].However,genemodiﬁcationinitselfcould
also induce tumorigenesis. The ideal method to purify the
cells would, therefore, not use genetic manipulation. We
recently obtained highly pure (>99% purity) human ES/iPS
cell-derived cardiomyocytes by ﬂuorescence-activated cell
sorting with the ﬂuorescent dye that labels mitochondria
[75]. This method involves no gene modiﬁcation and could
be used in the clinical setting. In addition, cell surface
proteins in nascent cardiomyocytes and cardiomyogenic
progenitors have been deﬁned as non genetic selection
markers for cardiomyocytes in the mouse ES/iPS cells [43,
76–80]. Such methodology to purify the objective cells
is constantly advancing the goals for cardiac regenerative
therapy.Long-termfollowupisnecessarytoanalyzerecipient
safety and prognosis, and all cell transplantation should be
tested in a large animal model before clinical usage.
5.GeneticandEpigenetic Proﬁle of iPSCelland
iPSCell-DerivedCardiomyocyte
There are several concerns about using iPS cell for regen-
erative medicine, because accumulating genetic and epi-
genetic proﬁles proved there remain important problems.
Initial study about epigenetic memory showed that iPS
cells derived from adult murine tissues harbour residual
DNA methylation signatures characteristic of their somatic
tissue of origin, which favours their diﬀerentiation along
lineagesrelatedtothedonorcell,whichsuggestanepigenetic
memory of the tissue of origin that may have inﬂuence on
directed diﬀerentiation for applications in disease modelling
or treatment [61]. In terms of pluripotent stem cell-
derived cardiomyocyte, iPS cell-derived cardiomyocytes are4 Stem Cells International
transcriptionally highly similar to ES cell-derived cardiomy-
ocytes, but iPS cell-derived cardiomyocyte also still possesses
the same somatic signature [81]. Exome analysis revealed
that hiPS cells acquire genetic modiﬁcations in addition
to epigenetic modiﬁcations which suggest extensive genetic
screening should become a standard procedure to ensure
hiPS cell safety before clinical usage [82]. Surprisingly latest
research showed that abnormal gene expression in some
cells diﬀerentiated from iPSCs can induce T-cell-dependent
immune response in syngeneic recipients in contrast to
d e r i v a t i v e so fE S C s[ 83]. The expression of these abnormal
minor antigens also may be due to epigenetic diﬀerence
between iPS cells and ES cells. These data suggests that
extensive genetic and epigenetic screening should become a
standard procedure to ensure hiPS cell safety before clinical
use.
6.Investigationof Patient-SpeciﬁciPSCells
Another expectation for iPS cells is the generation of human
disease-speciﬁc pluripotent stem cells, since established iPS
cells have identical genetic mutations to the source tissue.
Patient-speciﬁciPScellscandiﬀerentiateintoanytypeofcell,
allowing us to directly and repetitively analyse the diseased
cells in vitro. We now need to establish a revolutionary
assay system to elucidate the disease pathogenesis and to use
these patient-speciﬁc cells as a novel tool for drug screening
in combination with personalized medicine. Generally, it is
diﬃcult or impossible to take large samples from speciﬁc
patient tissues like neurons and cardiomyocytes and, even if
possible, such terminally diﬀerentiated cells cannot prolifer-
ate suﬃciently in vitro. For that reason, researchers in this
ﬁeld eagerly await this kind of promising stem cell.
To date, many kinds of patient-speciﬁc iPS cells have
been generated to diseases such as adenosine deaminase
deﬁciency, the Schwachman-Bodian-Diamond syndrome,
Gaucher’s disease, the Duchenne and Becker muscular
dystrophy, Parkinson’s disease, Huntington’s disease, type
1 diabetes mellitus, Down’s syndrome, the Lesch-Nyhan
syndrome, amyotrophic lateral sclerosis, spinal muscular
atrophy, and Fanconi’s anemia [84–88]. According to these
previous reports, iPS cells generated from a patient suﬀering
from early-onset disease are more likely to closely reproduce
the disease phenotypes. Recently, cardiac disease-speciﬁc iPS
cellswerealsoreported.OnelineisspeciﬁcfortheLEOPARD
syndrome, which is an autosomal dominant developmental
disorder belonging to a relatively prevalent class of inherited
RAS-mitogen-activated protein kinase signalling diseases
with pleomorphic eﬀects on several tissues and organ
systems [89]. The patient has a mutation in the PTPN11
gene, which encodes the SHP2 phosphatase. A major dis-
ease phenotype in patients with the LEOPARD syndrome
is hypertrophic cardiomyopathy. This study showed that
cardiomyocytes derived from LEOPARD syndrome iPS cells
are spontaneously hypertrophied in vitro and have a higher
degree of sarcomeric organization compared with cardiomy-
ocytes derived from human ES cells or wild-type iPS cells.
They concluded that these features correlate with a potential
hypertrophic state in patients. The other reported disease-
speciﬁc iPS cell line mimics congenital long QT syndromes
(LQTs) [90], which are heritable diseases associated with
prolongation of the QT interval on an electrocardiogram
and a high risk of sudden cardiac death due to ventricular
tachyarrhythmia. The authors generated iPS cells from two
patients with LQTs type 1 (LQTs 1), who have mutations
in the KCNQ1 gene encoding the repolarizing potassium
channel mediating the delayed rectiﬁer I (Ks) current.
Individual cardiomyocytes derived from LQTs 1 patients
showed prolonged action potentials compared with cells
from control subjects. Moreover, cardiomyocytes derived
from patients with LQTs 1 had an increased susceptibility to
catecholamine-induced tachyarrhythmia,and the phenotype
was attenuated by beta-blockade, which is one of the
most important clinical features of these syndromes. The
study showed that LQTs 1 patient-speciﬁc iPS cell-derived
cardiomyocytes totally reproduced the diseased phenotypes
in a clinical setting.
These studies into patient-speciﬁc iPS cells indicate a
tremendous potential for our increased understanding of
pathogenesis. Such technologies will be the basis for novel
industries in drug development and diagnostics.
7. Conclusions
Although iPS cells are artiﬁcial pluripotent stem cells, they
can produce chimeric animals in mouse and rat, and a
tetraploid complementation experiment demonstrated that
mouse iPS cells have the ability to autonomously generate
full-term mice. These results clariﬁed the existence of
pure pluripotent stem cells in iPS cells. Methods for the
generation of iPS cells have now undergone tremendous
and steady improvements. Although some problems remain
suchasgeneticmutationduringreprogramming,incomplete
epigenetic reprogramming, and undesired gene expression,
iPS cells could be applicable for regenerative medicine in
the future after solving those problems. Studies of disease
pathogenesis and drug discovery using this technology have
already been undertaken and will shed light on the discovery
of novel treatments for fatal cardiovascular diseases.
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